Detailed Narrative
H1 FY26 Financial Performance and Growth Drivers
Beta Drugs Ltd reported a 13% year-on-year revenue growth, reaching ₹204 crores in H1 FY26, despite production challenges due to adverse weather and audits. EBITDA increased by 17% to ₹47 crores, with margins expanding by 72 basis points to 23.08% from 22.36% in H1 FY25. PAT, excluding one-time📎 interest on convertible debentures, grew 18% to ₹28.71 crores, reflecting improved profitability and a PAT margin of 14.10%.
Strategic Market Expansion and Product Development
The company successfully completed a COFAPRIS audit in Mexico, filing 16 dossiers and planning 15 more, alongside clearing an INVIMA audit for injectables. Beta Drugs also secured approval for India's first NDDS of Methotrexate oral solution and initiated its first in-licensing deal for aesthetics fillers with an Italian company, targeting a ₹50-100 crore market share in 3-5 years from an estimated ₹1,000 crore market. The derma division itself grew 45% YoY and became profitable with ₹11.32 lakhs EBITDA.
Backward Integration and Capacity Enhancement
To reduce dependency on China and strengthen its DMFs, Beta Drugs acquired a licensed oncology intermediate plant for ₹9.45 crores, with an additional ₹15-20 crores planned for build-up and machinery over the next 6-8 months. This acquisition, along with increased capacity at the Adley formulation plant, positions the company for enhanced production and entry into regulated markets. Total additions to fixed assets in H1 FY26 amounted to approximately ₹25 crores.
Segmental Performance and Future Outlook
In H1 FY26, CDMO contributed 39% (₹79 crores) to total revenue, domestic owned brands 34% (₹60 crores), and exports 21% (₹43 crores). While H1 exports growth was 10%, management anticipates a significant acceleration in H2 FY26, targeting over ₹100 crores in exports due to tender seasonality. The company maintains its full-year revenue growth guidance of 20-25% and EBITDA margins of 23-25%, expecting strong H2 performance to compensate for the H1 growth of 13%.
Working Capital and Margin Dynamics
The company experienced a marginal increase in working capital days (from 92 to 95) and receivables days (from 103 to 108), attributed to higher sales volumes. Consolidated gross profit margins saw a 1.5% decline YoY, primarily due to product mix shifts within the CDMO segment towards lower-margin Platin group products, which constitute less than 7% of overall revenue. However, overall EBITDA margins improved, and management expects this trend to continue, with standalone Beta margins improving as regulated market export sales commence.
Regulatory and Operational Updates
Beta Drugs received principal approval from NSE to migrate to the main board within 10 days, enhancing its market visibility. The long-delayed Europe approval for its cytotoxic suspension plant is now expected in Q1 FY27 (Jan-Mar 2026), following audit confirmation by mid-December. The company is also actively exploring entry into the biosimilars segment, with launches anticipated in 3-4 years, and plans to file 150-plus doses in regulated markets over the next two years.